Literature DB >> 29077640

Risk and Causes of Death among Former National Football League Players (1986-2012).

Andrew E Lincoln1,1,1, Robert A Vogel1, Thomas W Allen1, Reginald E Dunn1,1, Kezia Alexander1,1, Nathaniel D Kaufman1,1, Andrew M Tucker1.   

Abstract

PURPOSE: Previous research identified decreased overall and cardiovascular mortality for National Football League (NFL) players from the 1959-1988 era. The present study explored the mortality risk among recent NFL players who played in an era of heavier linemen and nearly year-round physical conditioning.
METHODS: This cohort study included 9778 former NFL players with at least 1 yr in the NFL whose last season was between 1986 and 2012. Players' pension fund records were matched to the National Death Index to determine vital status, date of death, and cause of death. Standardized mortality ratios (SMR) compared player mortality through 2014 with US men of the same age, race, and calendar year. Cox proportional hazards models assessed the effect of player characteristics on overall and cardiovascular mortality.
RESULTS: Two percent (n = 227) of players were deceased, with a median age at death of 38 yr (range, 23-61 yr). The most common major causes of death were diseases of the heart (n = 47; 21%), violence (n = 39; 17%), and transportation injuries (n = 34; 15%). Risk of death was significantly lower than the general population for overall mortality (SMR, 0.46, 95% confidence interval (CI), 0.40-0.52), cardiovascular disease (SMR, 0.65; 95% CI, 0.50-0.84), and other major causes. Players with playing-time body mass index (BMI) of >35 kg·m had significantly higher cardiovascular disease mortality (SMR, 2.20; 95% CI, 1.32-3.44) than did the general population and higher overall mortality risk (standardized rate ratio, 3.84; 95% CI, 2.66-5.54) than did players with a BMI of <30 kg·m.
CONCLUSIONS: Consistent with an earlier NFL cohort and other elite athlete populations, the overall and cardiovascular mortality risk of this NFL cohort was significantly lower than that of the general US male population, likely attributable to a healthy worker effect and less smoking.However, players with the highest playing-time BMI exhibited elevated cardiovascular mortality risk.

Entities:  

Mesh:

Year:  2018        PMID: 29077640     DOI: 10.1249/MSS.0000000000001466

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  15 in total

1.  Weight Gain, Hypertension, and the Emergence of a Maladaptive Cardiovascular Phenotype Among US Football Players.

Authors:  Jonathan H Kim; Casey Hollowed; Chang Liu; Ahmed Al-Badri; Ayman Alkhoder; Morgan Dommisse; Zaina Gowani; Arthur Miller; Parker Nguyen; Ganesh Prabakaran; Arianna Sidoti; Mohamad Wehbe; Angelo Galante; Carla L Gilson; Craig Clark; Yi-An Ko; Arshed A Quyyumi; Aaron L Baggish
Journal:  JAMA Cardiol       Date:  2019-12-01       Impact factor: 14.676

2.  Metabolic Alterations Differentiating Cardiovascular Maladaptation from Athletic Training in American-Style Football Athletes.

Authors:  Jason V Tso; Chang Liu; Casey G Turner; Karan Uppal; Ganesh Prabakaran; Kiran Ejaz; Aaron L Baggish; Dean P Jones; Arshed A Quyyumi; Jonathan H Kim
Journal:  Med Sci Sports Exerc       Date:  2022-05-26

3.  Association between race and maladaptive concentric left ventricular hypertrophy in American-style football athletes.

Authors:  Jason V Tso; Casey G Turner; Chang Liu; Angelo Galante; Carla R Gilson; Craig Clark; Herman A Taylor; Arshed A Quyyumi; Aaron L Baggish; Jonathan H Kim
Journal:  Br J Sports Med       Date:  2021-08-13       Impact factor: 18.473

4.  Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Risk in American Football.

Authors:  Jason Tso; Casey Hollowed; Chang Liu; Ayman Alkhoder; Morgan Dommisse; Zaina Gowani; Arthur Miller; Grace Nguyen; Parker Nguyen; Ganesh Prabakaran; Mohamad Wehbe; Angelo Galante; Carla R Gilson; Craig Clark; Thomas Marshall; Gene Patterson; Arshed A Quyyumi; Aaron L Baggish; Jonathan H Kim
Journal:  Med Sci Sports Exerc       Date:  2020-12

Review 5.  Chronic Traumatic Encephalopathy in Professional American Football Players: Where Are We Now?

Authors:  Tharmegan Tharmaratnam; Mina A Iskandar; Tyler C Tabobondung; Iqdam Tobbia; Prasaanthan Gopee-Ramanan; Taylor A Tabobondung
Journal:  Front Neurol       Date:  2018-06-19       Impact factor: 4.003

Review 6.  A Systematic Review of Etiological Risk Factors Associated With Early Mortality Among National Football League Players.

Authors:  Arthur H Owora; Brittany L Kmush; Bhavneet Walia; Shane Sanders
Journal:  Orthop J Sports Med       Date:  2018-12-19

7.  Arrhythmias and Adaptations of the Cardiac Conduction System in Former National Football League Players.

Authors:  Philip Aagaard; Shishir Sharma; David A McNamara; Parag Joshi; Colby R Ayers; James A de Lemos; Andrew E Lincoln; Bryan Baranowski; Kyle Mandsager; Elizabeth Hill; Lon Castle; James Gentry; Richard Lang; Reginald E Dunn; Kezia Alexander; Andrew M Tucker; Dermot Phelan
Journal:  J Am Heart Assoc       Date:  2019-07-24       Impact factor: 5.501

8.  Mortality Among Professional American-Style Football Players and Professional American Baseball Players.

Authors:  Vy T Nguyen; Ross D Zafonte; Jarvis T Chen; Kalé Z Kponee-Shovein; Sabrina Paganoni; Alvaro Pascual-Leone; Frank E Speizer; Aaron L Baggish; Herman A Taylor; Lee M Nadler; Theodore K Courtney; Ann Connor; Marc G Weisskopf
Journal:  JAMA Netw Open       Date:  2019-05-03

Review 9.  Blood Biomarker Profiling and Monitoring for High-Performance Physiology and Nutrition: Current Perspectives, Limitations and Recommendations.

Authors:  Charles R Pedlar; John Newell; Nathan A Lewis
Journal:  Sports Med       Date:  2019-12       Impact factor: 11.136

10.  Association of Professional Football Cumulative Head Impact Index Scores With All-Cause Mortality Among National Football League Players.

Authors:  Brittany L Kmush; Madeline Mackowski; Justin Ehrlich; Bhavneet Walia; Arthur Owora; Shane Sanders
Journal:  JAMA Netw Open       Date:  2020-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.